Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00659893
Registration number
NCT00659893
Ethics application status
Date submitted
15/04/2008
Date registered
17/04/2008
Date last updated
14/09/2015
Titles & IDs
Public title
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
Query!
Scientific title
A Multi-center, Open Label, Dose-area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days to Treatment Area(s) of up to a Total of 100 cm2 in Patients With Actinic Keratoses on the Extensor (Dorsal Aspect) Forearm(s)
Query!
Secondary ID [1]
0
0
PEP005-022
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Actinic Keratosis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PEP005 Topical gel
Experimental: 1 - Cohort 1 One 25 cm2 treatment area; on one arm
Experimental: 2 - Cohort 2 One 50cm2 contiguous treatment area; on one arm
Experimental: 3 - Cohort 3 Two 25cm2 treatment areas; one on each arm
Experimental: 4 - Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
Experimental: 5 - Cohort 5 One 75cm2 contiguous treatment area; on one arm
Experimental: 6 - Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
Experimental: 7 - Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
Experimental: 8 - Cohort 8 One 100cm2 contiguous treatment area; on one arm
Treatment: Drugs: PEP005 Topical gel
0.05%, two day dose
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and tolerability (incidence of AEs, SAEs and skin responses)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Screening to End of Study (Day 57)
Query!
Eligibility
Key inclusion criteria
* Must be male and at least 18 years of age.
* A 100 cm2 contiguous treatment area on each of the right and left extensor (dorsal aspect) forearms, each containing a minimum of 5 AK lesions.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing): within 2 weeks and within 2 cm of the selected treatment area(s).
* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system: within 4 weeks.
* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and within 2 cm of the selected treatment area(s).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
64
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
St George Dematology and Skin and Cancer Centre - Kogarah, Sydney
Query!
Recruitment hospital [2]
0
0
South East Dermatology, Belmont Specialist Centre - Carina Heights, Brisbane
Query!
Recruitment hospital [3]
0
0
Skin and Cancer Foundation - Carlton, Melbourne
Query!
Recruitment hospital [4]
0
0
St John of God Dermatology - Subiaco, Perth
Query!
Recruitment hospital [5]
0
0
Burswood Dermatology - Victoria Park, Perth
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah, Sydney
Query!
Recruitment postcode(s) [2]
0
0
4152 - Carina Heights, Brisbane
Query!
Recruitment postcode(s) [3]
0
0
3053 - Carlton, Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6008 - Subiaco, Perth
Query!
Recruitment postcode(s) [5]
0
0
6100 - Victoria Park, Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New Jersey
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Texas
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Peplin
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00659893
Query!
Trial related presentations / publications
Anderson L, Jarratt M, Schmieder G, Shumack S, Katsamas J, Welburn P. Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. J Clin Aesthet Dermatol. 2014 Dec;7(12):19-29.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
George Schmieder, DO
Query!
Address
0
0
Park Avenue Dermatology
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00659893
Download to PDF